Insmed (INSM) Net Equity Issued and Repurchased (2011 - 2025)
Insmed's (INSM) quarterly Net Equity Issued and Repurchased came in at -$256000.0 in Q3 2025, down 100.07% year-on-year from $371.0 million in Q3 2024, and down 2033.33% quarter-over-quarter from -$12000.0 in Q4 2024.
Insmed (INSM) Net Equity Issued and Repurchased (2011 - 2025) Analysis & Trends
Insmed's Net Equity Issued and Repurchased history runs 11 years deep, the most recent figure standing at -$256000.0 for Q3 2025.
- On a quarterly basis, Net Equity Issued and Repurchased fell 100.07% year-over-year to -$256000.0 in Q3 2025; TTM through Dec 2025 was $370.7 million, a 23.63% decrease from a year earlier, with the FY2025 full-year figure at $823.3 million, down 24.06% from the prior year.
- Net Equity Issued and Repurchased retreated to -$256000.0 in Q3 2025 per INSM's latest filing, from -$12000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $371.0 million in Q3 2024 and bottomed at -$256000.0 in Q3 2025.
- The 4-year median for Net Equity Issued and Repurchased is $73.9 million (2022), against an average of $129.6 million.
- Across the five-year window, Net Equity Issued and Repurchased plunged 55.77% in 2023 and slumped 100.07% in 2025, its largest moves.
- Year by year, Net Equity Issued and Repurchased stood at $258.8 million in 2022, then plunged by 55.77% to $114.5 million in 2023, then plunged by 100.01% to -$12000.0 in 2024, then tumbled by 2033.33% to -$256000.0 in 2025.
- Per Business Quant, the three latest INSM Net Equity Issued and Repurchased figures stand at -$256000.0 (Q3 2025), -$12000.0 (Q4 2024), and $371.0 million (Q3 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Insmed | 23.26 Bn | 22.03 Bn | 258.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -256,000.00 |
| Sep 30, 2025 | -256,000.00 |
| Dec 31, 2024 | -12,000.00 |
| Dec 31, 2024 | -12,000.00 |
| Sep 30, 2024 | 370.98 Mn |
| Sep 30, 2024 | 370.98 Mn |
| Dec 31, 2023 | 114.46 Mn |
| Dec 31, 2023 | 114.46 Mn |
| Dec 31, 2022 | 258.77 Mn |
| Dec 31, 2022 | 258.77 Mn |
| Sep 30, 2022 | 33.38 Mn |
| Sep 30, 2022 | 33.38 Mn |
| Dec 31, 2020 | 1,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | -47,000.00 |
| Sep 30, 2020 | -47,000.00 |
| Sep 30, 2019 | -104,000.00 |
| Sep 30, 2019 | -104,000.00 |
| Sep 30, 2017 | 377.70 Mn |
| Sep 30, 2017 | 377.70 Mn |